Defining Lesional, Perilesional and Unaffected Skin in Hidradenitis Suppurativa: Proposed Recommendations for Clinical Trials and Translational Research Studies

JW Frew¹, K Navrazhina¹,², A Byrd³, A Garg⁴, JR Ingram⁵, JS Kirby⁶, MA Lowes¹, H Naik⁷, V Piguet⁸,⁹, EP Prens¹⁰

¹Laboratory of Investigative Dermatology, The Rockefeller University, NY, USA
²Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, Weill Cornell University, NY, USA
³Department of Dermatology, Howard University, Washington DC, USA
⁴Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, USA
⁵Institute of Infection & Immunity, Cardiff University, University Hospital of Wales, Cardiff, UK
⁶Department of Dermatology, Penn State Hershey Medical Center, Hershey, PA, USA.
⁷Department of Dermatology, University of California, San Francisco, USA
⁸Division of Dermatology, Women’s College Hospital, Toronto, Ontario, Canada
⁹Division of Dermatology, Dept of Medicine, University of Toronto, Toronto, Ontario, Canada
¹⁰Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands

Word Count: 631
Figure Count: 1

Corresponding Author:
John W Frew
Laboratory of Investigative Dermatology,
The Rockefeller University
1230 York Avenue
New York, NY, United States of America
Ph: +1-212-327-7153
Fax: +1-212-327-8232
Email: jfrew@rockefeller.edu

Key Words: Hidradenitis Suppurativa, Biopsy, Clinical Trial, Guidelines, Lesion, Definition
Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory skin condition for which the pathogenesis is not completely elucidated. With the increase in HS-related research comes the need to enhance reproducibility, quality, accuracy and reproducibility of scientific methods. Unlike other inflammatory dermatoses such as psoriasis or atopic dermatitis, HS lesions are morphologically diverse and include nodules, abscesses, tunnels and fibrosis in various permutations and combinations admixed in the same anatomical region. This makes general definitions as ‘lesional’ and ‘non-lesional’ insufficient for HS-related investigations. A definition for non-lesional skin is lacking. Accurate assessment of the pathophysiologic changes in HS lesions (and the response to therapeutics) requires standardized definitions of lesional, perilesional and unaffected skin biopsies. This is especially pertinent given the well-characterized compartmentalization of cytokines in HS, indicating that serum inflammatory markers may not accurately reflect the inflammatory milieu of lesional HS tissue. An additional complicating factor is the unique inflammatory environment of healthy axillae, groin and submammary folds with an increased IL-17 and innate immune signature, which makes it crucial to ensure that unaffected skin samples are taken from a site that ensures an accurate comparison. For control specimens, or samples from healthy volunteers, the use of surgical discard from abdominoplasty is problematic given the unique immunological milieu of apocrine-rich (axillary, inguinal, submammary) skin. The use of region-matched control tissue is vital to avoid overestimation of the relative change of Th17 and other innate immune markers. Ideally, healthy control skin should also be matched for other criteria such as age, gender, and ethnicity.
Examination of the existing literature\textsuperscript{4} pertaining to inflammatory mediators in HS identified two high-quality studies with \textit{a priori} definitions of biopsy sites\textsuperscript{5,6}. Lesional skin was defined as the edge of an inflammatory lesion, perilesional as normal-appearing skin 2cm away from the inflammatory lesion, and unaffected skin as normal-appearing skin $\geq 10$cm distant. An important caveat is that the reference lesion in these studies requires \textit{a priori} definition. For the majority of published studies this was an inflammatory nodule. Biopsies for tunnels may require deeper full-dermal tissue sampling. It is known that histologically fibrotic tissue attenuates the levels of inflammatory mediators compared with non-fibrotic tissue, and the invasive proliferative gelatinous mass (IPGM) of HS tunnels has a specific cytokine signature distinct from lesional tissue\textsuperscript{7}. Therefore, classifying the reference lesion (nodule, tunnel, hypertrophic scar) is crucial for comparison across studies. The presence of dermal tunnels may introduce unintended pathology which can be difficult to appreciate clinically, and hence ultrasound is a useful non-invasive assessment tool to identify dermal tunnels and deep abscesses in order to avoid inadvertent biopsy of a lesion in place of a control sample.

In the context of clinical trials, assessment of lesional tissue is often an exploratory endpoint\textsuperscript{8} given the lack of biomarkers in HS. While the data are not considered a primary or secondary endpoint, they do contribute to the existing knowledge of pathophysiology of disease. Therefore, based upon the existing literature (and the authors’ combined experience) we propose the following recommendations: (1) samples should be obtained from three sites: lesional, perilesional, and unaffected skin; (2) the definitions of lesional, perilesional and
unaffected skin as presented in Figure 1; (3) the anatomic region of the lesion should be recorded; (4) the lesion morphology should be classified (e.g. inflammatory nodule, abscess, tunnel, etc.); and (5) unaffected skin of HS patients and control (taken from healthy volunteers) samples, should be region matched to lesional and perilesional samples (i.e. within the same anatomical region). In the absence of clear standards for HS tissue sampling, these recommendations seek to begin this process. Consensus among stakeholders is needed on a valid and reliable approach to tissue sampling, so that these strategies can be implemented in future studies. The next step is to create a coherent consensus and this work is underway.

References:

1) Saunte DML, Jemec GBJ Hidradenitis Suppurativa: Advances in Diagnosis and Treatment JAMA 2017;318(2):2019-2032


5) Moran B, Sweeney CM, Hughes R, Malara A, Kirthi S et al Hidradenitis Suppurativa is Characterized by Dysregulation of the Th17:Treg cell axis, which is corrected by anti TNF therapy J Invest Dermatol 2017;137(11):2389-2395


Figure Legends:

Figure 1: Biopsy Definition Recommendations for Hidradenitis Suppurativa